British Patient Capital

British Patient Capital
Name	British Patient Capital
Formation	2018
Type	Limited Partnership
Headquarters	London
Parent organization	British Business Bank
Key people	André da Costa (CEO), Ben Wallace (Chancellor of the Exchequer)
Region served	United Kingdom

British Patient Capital is a UK-based investment vehicle established to provide long-term capital to innovative United Kingdom companies through equity and co-investments. It was created as a wholly owned subsidiary of the British Business Bank to address perceived gaps in late-stage venture and growth funding while coordinating with private asset managers, limited partners, and public institutions. The initiative interacts with actors across the City of London, Scottish National Investment Bank, European Investment Fund, UK Research and Innovation, Big Society Capital, and international investors.

History and Establishment

The vehicle was announced in the aftermath of debates in the House of Commons about regional finance and industrial strategy, drawing on precedents such as the Enterprise Investment Scheme and recommendations from the Patient Capital Review chaired by Sir Damon Buffini. It launched following consultations with stakeholders including the Department for Business and Trade, the Institute for Fiscal Studies, and industry groups like the British Private Equity & Venture Capital Association. Its formation was influenced by comparative models such as the European Investment Fund, the Temasek Holdings approach in Singapore, and the Canada Pension Plan Investment Board's growth allocations, while reacting to market conditions after the 2008 financial crisis and in the context of debates around Brexit and UK industrial policy.

Structure and Governance

Organisationally, the vehicle operates as an arm’s-length manager under the ownership of the British Business Bank and uses a limited partnership fund model common to Blackstone, KKR, and CVC Capital Partners. Governance combines oversight from non-executive directors, an independent board, and investment committees similar to arrangements at University of Cambridge Investment Office endowments and sovereign funds like Abu Dhabi Investment Authority. Regulatory interaction occurs with the Financial Conduct Authority and reporting aligns with standards used by National Audit Office-audited public entities. Appointment processes for senior roles have been compared with selections at Bank of England and Barclays boards, and risk frameworks borrow from practices at Goldman Sachs and the World Bank.

Investment Strategy and Portfolio

The investment mandate focuses on minority and majority equity stakes, co-investments, and fund-of-funds commitments targeting late-stage venture capital and growth capital across sectors such as fintech, life sciences, deep tech, and clean energy. Portfolio construction mirrors approaches used by Sequoia Capital, Accel Partners, and Index Ventures, while collaborating with managers like Octopus Ventures, Balderton Capital, and Atomico. Notable portfolio companies and fund partners have included firms in the lineage of Deliveroo, Revolut, Improbable Worlds, Oxford Nanopore Technologies, and Ceres Power-type innovators (examples of sectoral peers). Allocation strategies reference benchmarking practices from MSCI, FTSE Russell, and institutional investors such as Teachers' Retirement System of Texas.

Funding and Financial Performance

Initial capitalisation drew on a multi-year commitment from public funds administered by the British Business Bank and budgetary allocations debated in the Treasury Select Committee. Co-investment and leverage have been structured to attract institutional partners including Legal & General, Standard Life Aberdeen, Nationwide Building Society, and foreign sovereign wealth entities like Qatar Investment Authority in comparable models. Performance reporting uses internal rate of return (IRR) metrics and comparative multiples similar to disclosures by Hermes Investment Management and Pension Protection Fund. Financial results have been assessed in policy reviews by bodies such as the National Audit Office and think tanks including the Resolution Foundation; outcomes have been presented alongside macro indicators like UK GDP growth and Office for National Statistics investment data.

Impact and Outcomes

The programme aims to scale companies to exits via public listings on markets such as the London Stock Exchange or trade sales to buyers like TPG Capital, Silver Lake Partners, or strategic acquirers including ARM Holdings-style buyers. Reported impacts include job creation across regions including Manchester, Edinburgh, Cambridge, and Bristol, and increased follow-on funding from international investors such as SoftBank and Baidu. Evaluations reference comparisons to the impacts of the Apollo Program-style long-term funding narratives and regional development models like the Northern Powerhouse and Midlands Engine initiatives. Collaboration with research institutions like University of Oxford, Imperial College London, and University of Cambridge underpins investments in life sciences and deep tech.

Criticisms and Controversies

Critiques have come from Members of Parliament, academic commentators at institutions like the London School of Economics, and industry bodies questioning additionality, market distortion, and public return on investment, echoing debates around Privatisation and public sponsorship seen in controversies involving Royal Bank of Scotland and Green Investment Bank. Concerns include governance scrutiny similar to inquiries into UK Export Finance and perceived crowding effects noted by the Competition and Markets Authority. Questions have also been raised about sector concentration, alignment with regional levelling-up agendas championed by figures associated with the Levelling Up White Paper, and transparency compared with reporting standards used by National Audit Office and international peers such as Australian Future Fund.

Category:Investment companies of the United Kingdom